<p class="doc-ti" id="d1e39-5-1" style="font-weight: 600; font-style: italic; text-align: center;">COMMISSION IMPLEMENTING DECISION (EU) 2017/2201</p><p class="doc-ti" style="font-weight: 600; font-style: italic; text-align: center;">of 27 November 2017</p><p class="doc-ti" style="font-weight: 600; font-style: italic; text-align: center;">authorising the placing on the market of 2′-fucosyllactose produced with <span class="italic">Escherichia coli</span> strain BL21 as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council</p><p class="doc-ti" style="font-weight: 600; font-style: italic; text-align: center;"> <span class="sp-normal"> <span class="italic">(notified under document C(2017) 7662)</span> </span> </p><p class="doc-ti" style="font-weight: 600; font-style: italic; text-align: center;">(Only the German text is authentic)</p><section><p class="normal">THE EUROPEAN COMMISSION,</p><p class="normal">Having regard to the Treaty on the Functioning of the European Union,</p><p class="normal">Having regard to Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and novel food ingredients, and in particular Article 7 thereof,</p><p class="normal">Whereas:</p><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(1)</p> </td> <td valign="top"> <p class="normal">On 4 August 2014, the company Jennewein Biotechnologie GmbH made a request to the competent authority of the Netherlands to place powder and liquid concentrate of the oligosaccharide 2′-fucosyllactose produced with a genetically modified strain of <span class="italic">Escherichia coli</span> BL21 on the Union market as novel food ingredient within the meaning of point (d) of Article 1(2) of Regulation (EC) No 258/97. The target population is the infant population.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(2)</p> </td> <td valign="top"> <p class="normal">2′-fucosyllactose falls outside the scope of Regulation (EC) No 1829/2003 of the European Parliament and of the Council as the genetically modified strain of <span class="italic">Escherichia coli</span> BL21 is used as a processing aid and the material derived from the genetically modified microorganism is not present in the novel food.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(3)</p> </td> <td valign="top"> <p class="normal">On 3 June 2016, the competent authority of the Netherlands issued its initial assessment report. In that report it came to the conclusion that powder and liquid concentrate of the oligosaccharide 2′-fucosyllactose produced with a genetically modified strain of <span class="italic">Escherichia coli</span> BL21 meets the criteria for novel food ingredients set out in Article 3(1) of Regulation (EC) No 258/97.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(4)</p> </td> <td valign="top"> <p class="normal">On 13 June 2016, the Commission forwarded the initial assessment report to the other Member States.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(5)</p> </td> <td valign="top"> <p class="normal">Reasoned objections were raised within the 60-day period laid down in the first subparagraph of Article 6(4) of Regulation (EC) No 258/97. In particular, objections concerning elevated intake levels of 2′-fucosyllactose were raised. In accordance with Article 7(1) of Regulation (EC) No 258/97, a decision should be adopted taking into account the objections raised. The applicant consequently modified the request concerning the maximum amount of 2′-fucosyllactose in infant formulae and follow- on formulae. That change and additional explanations provided by the applicant alleviated the concerns to the satisfaction of Member States and of the Commission.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(6)</p> </td> <td valign="top"> <p class="normal">Regulation (EU) No 609/2013 of the European Parliament and of the Council lays down requirements for food intended for infants and young children. The use of 2′-fucosyllactose powder and liquid concentrate should be authorised without prejudice to that Regulation and to any other legislation that applies in parallel to Regulation (EC) No 258/97.</p> </td> </tr> </tbody> </table><table border="0" cellpadding="0" cellspacing="0" width="100%"> <col width="4%"/> <col width="96%"/> <tbody> <tr> <td valign="top"> <p class="normal">(7)</p> </td> <td valign="top"> <p class="normal">The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,</p> </td> </tr> </tbody> </table><p class="normal">HAS ADOPTED THIS DECISION:</p></section> <section><p class="ti-art" id="d1e163-5-1" style="font-style: italic; text-align: center;">Article 1</p><p class="normal">Without prejudice to Regulation (EU) No 609/2013, 2′-fucosyllactose powder and liquid concentrate as specified in Annex I to this Decision may be placed on the Union market as a novel food ingredient for the uses defined and at the maximum level established in Annex II to this Decision.</p></section> <section><p class="ti-art" id="d1e168-5-1" style="font-style: italic; text-align: center;">Article 2</p><p class="normal">The designation of 2′-fucosyllactose powder and liquid concentrate authorised by this Decision on the labelling of the foodstuffs shall be ‘2′-fucosyllactose’ for the powder and for the liquid concentrate.</p></section> <section><p class="ti-art" id="d1e177-5-1" style="font-style: italic; text-align: center;">Article 3</p><p class="normal">This Decision is addressed to Jennewein Biotechnologie GmbH, Maarweg 32, 53619 Rheinbreitbach, Germany.</p></section>